{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:32:10Z","timestamp":1792740730800,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T00:00:00Z","timestamp":1376352000000},"content-version":"vor","delay-in-days":104,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["RDA\/03\/07\/014"],"award-info":[{"award-number":["RDA\/03\/07\/014"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["PDF-2012-05-245"],"award-info":[{"award-number":["PDF-2012-05-245"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["PDA\/02\/06\/088"],"award-info":[{"award-number":["PDA\/02\/06\/088"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.vaccine.2013.03.034","type":"journal-article","created":{"date-parts":[[2013,4,6]],"date-time":"2013-04-06T03:22:01Z","timestamp":1365218521000},"page":"2638-2646","source":"Crossref","is-referenced-by-count":108,"title":["Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact"],"prefix":"10.1016","volume":"31","author":[{"given":"Hannah","family":"Christensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. John","family":"Edmunds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline L.","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.03.034_bib0005","unstructured":"Mortality statistics: Deaths registered in 2010 (Series DR) Table 5: Office for National Statistics, Available from http:\/\/www.ons.gov.uk\/ons\/rel\/vsob1\/mortality-statistics--deaths-registered-in-england-and-wales--series-dr-\/2010\/dr-tables-2010.xls; 2011 [accessed 30.05.12]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0010","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0015","first-page":"364","article-title":"Meningococcal disease: challenges in prevention and management","volume":"17","author":"Leake","year":"2000","journal-title":"Infect Med"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0020","unstructured":"PL CPHO (1999)1: Introduction of immunisation against Group C Meningococcal infections: Department of Health, Available from http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Lettersandcirculars\/Professionalletters\/Chiefpharmaceuticalofficerletters\/DH_4066113; 1999 [accessed 30.05.12]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0025","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the Meningococcal C Conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0030","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0035","unstructured":"Invasive Neisseria meningitidis in Europe. London: EU-IBIS Network Health Protection Agency, Available from http:\/\/www.hpa-bioinformatics.org.uk\/euibis\/documents\/2006_meningo.pdf; 2011 [accessed 30.05.11]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0040","unstructured":"Meningococcal Reference Unit isolates of Neisseria meningitidis: England and Wales, by serogroup & epidemiological year, 1998\/99-2009\/10: Health Protection Agency, Available from http:\/\/www.hpa.org.uk\/web\/HPAweb&HPAwebStandard\/HPAweb_C\/1234859711901; 2011 [accessed 12.11.12]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis","volume":"322","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0050","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0055","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0060","unstructured":"Macey RI, Oster G. Berkeley Madonna. 8.3.14 ed, Available from http:\/\/www.berkeleymadonna.com\/index.html; 2006."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0065","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1002\/(SICI)1097-0258(19991215)18:23<3263::AID-SIM315>3.0.CO;2-3","article-title":"Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective","volume":"18","author":"Edmunds","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0070","unstructured":"Dynamic transmission modeling: A report of the ISPOR-SMDM modeling good research practices task force-5 (draft), Available from http:\/\/www.ispor.org\/workpaper\/modeling_methods\/dynamic-transmission-modeling.asp; [accessed 12.11.12]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0075","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1136\/jnnp.2003.034272","article-title":"Difficult and recurrent meningitis","volume":"75","author":"Ginsberg","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0080","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/oxfordjournals.aje.a121574","article-title":"Observations on asymptomatic infections with Neisseria meningitidis","volume":"98","author":"Altmann","year":"1973","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0085","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1128\/JCM.38.6.2311-2316.2000","article-title":"Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination","volume":"38","author":"Ala\u2019Aldeen","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0090","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1017\/S0950268898008930","article-title":"Dynamics of the meningococcal carrier state and characteristics of the carrier strains: a longitudinal study within three cohorts of military recruits","volume":"121","author":"Andersen","year":"1998","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0095","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/JCM.10.3.302-307.1979","article-title":"Rapid serogroup identification of Neisseria meningitidis by using antiserum agar: prevalence of serotypes in a disease-free military population","volume":"10","author":"Craven","year":"1979","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0100","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0105","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1371\/journal.pmed.0050074","article-title":"Social contacts and mixing patterns relevant to the spread of infectious diseases","volume":"5","author":"Mossong","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0110","unstructured":"Department of Health. National Schedule of Reference Costs 2008-09 for NHS Trusts and PCTs combined, Available from http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_111591; 2010 [accessed 20.05.11]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0115","unstructured":"National Institute for Health and Clinical Excellence. CG102 Bacterial meningitis and meningococcal septicaemia: quick reference guide (amended), Available from http:\/\/guidance.nice.org.uk\/CG102\/QuickRefGuide\/pdf\/English; 2010 [accessed 20.05.11]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1473-3099(10)70048-7","article-title":"Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis","volume":"10","author":"Edmond","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0125","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1016\/S0264-410X(03)00562-0","article-title":"Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies","volume":"21","author":"Ruedin","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0130","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/520303","article-title":"Complications and sequelae of meningococcal disease in Quebec, Canada, 1990\u20131994","volume":"26","author":"Erickson","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0135","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/archpedi.162.11.1036","article-title":"Long-term health status in childhood survivors of meningococcal septic shock","volume":"162","author":"Buysse","year":"2008","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0140","unstructured":"Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Discussion paper 172, Available from http:\/\/www.york.ac.uk\/inst\/che\/pdf\/DP172.pdf; 1999 [accessed 15.05.08]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0145","unstructured":"British National Formulary [Homepage on the Internet], Available from http:\/\/www.bnf.org\/bnf\/; [accessed 22.01.13]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0150","first-page":"220","article-title":"Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign","volume":"5","author":"Trotter","year":"2002","journal-title":"Commun Dis Public Health"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0155","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1016\/j.vaccine.2005.06.034","article-title":"Costs of running a universal adolescent hepatitis B vaccination programme","volume":"23","author":"Wallace","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0160","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/bmj.324.7341.809","article-title":"Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales","volume":"324","author":"Trotter","year":"2002","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0165","unstructured":"Curtis L. Unit Costs of Health and Social Care 2009, Available from http:\/\/www.pssru.ac.uk\/pdf\/uc\/uc2009\/uc2009.pdf; 2009 [accessed 20.05.11]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0170","first-page":"530","article-title":"Comparing the cost of nurse practitioners and GPs in primary care: modelling economic data from randomised trials","volume":"56","author":"Hollinghurst","year":"2006","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0320","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0180","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0185","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0190","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CVI.00027-10","article-title":"Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in Group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational Group B meningococcal vaccine","volume":"17","author":"Lucidarme","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0200","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/0272989X9701700414","article-title":"Estimating CE Ratios under second-order uncertainty","volume":"17","author":"Stinnett","year":"1997","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0205","unstructured":"Guide to the methods of technology appraisal, Available from http:\/\/www.nice.org.uk\/aboutnice\/howwework\/devnicetech\/technologyappraisalprocessguides\/guidetothemethodsoftechnologyappraisal.jsp; 2008 [accessed 23.06.08]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0210","series-title":"The green book. Appraisal and evaluation in central government","author":"Treasury","year":"2003"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0215","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0272989X05284109","article-title":"Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model","volume":"26","author":"Trotter","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0220","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ije\/29.1.180","article-title":"Mathematical modelling of infection and disease due to Neisseria meningitidis and Neisseria lactamica","volume":"29","author":"Coen","year":"2000","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0225","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1016\/j.vaccine.2009.01.092","article-title":"On the relationship between meningococcal transmission dynamics and disease: remarks on humoral immunity","volume":"27","author":"Guzzetta","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/524041","article-title":"Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States","volume":"46","author":"Ortega-Sanchez","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0235","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0240","unstructured":"Current Epidemiology of Invasive Pneumococcal Disease (IPD): Health Protection Agency, Available from http:\/\/www.hpa.org.uk\/Topics\/InfectiousDiseases\/InfectionsAZ\/Pneumococcal\/EpidemiologicalDataPneumococcal\/CurrentEpidemiologyPneumococcal\/; 2010 [accessed 30.05.11]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0245","unstructured":"Joint Committee on Vaccination and Immunisation. Minutes of the meeting held on 18 February 2009: Joint Committee on Vaccination and Immunisation, Available from http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/@dh\/@ab\/documents\/digitalasset\/dh_097411.pdf; 2009 [accessed 30.05.11]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0250","unstructured":"Novartis Vaccines. A Phase 3 observer blind randomized, multi-center, controlled study to evaluate the effect of Novartis vaccine's Meningococcal B Recombinant and MenACWY conjugate vaccines on pharyngeal carriage of N. meningitidis in young adults. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US), Available from http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01214850; NLM Identifier: NCT01214850 [accessed 07.03.13]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0255","unstructured":"Novartis Vaccines. Persistence of antibody levels and response to fifth or third Meningococcal B Recombinant Vaccine in 4-year old healthy children who previously participated in study V72P12E1. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01717638; NLM Identifier: NCT01717638 [accessed 07.03.13]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0260","doi-asserted-by":"crossref","first-page":"A5","DOI":"10.1136\/adc.2010.186338.11","article-title":"Outcomes of meningococcal serogroup B disease: findings from a nationally representative case-control study","volume":"95","author":"Viner","year":"2010","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0265","unstructured":"Wright C, Wordsworth R, Glennie L. Counting the cost: a severe case of bacterial menigitis, Available from http:\/\/www.meningitis.org\/assets\/x\/53379; 2011 [accessed 24.03.12]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0270","unstructured":"Wright C, Wordsworth R, Glennie L. Counting the cost: a severe case of meningococcal septicaemia. Available from http:\/\/www.meningitis.org\/assets\/x\/53382; 2011 [accessed 24.03.12]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0275","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/aje\/kwj317","article-title":"Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents","volume":"164","author":"Wallinga","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0280","unstructured":"Table 2.1 Deaths: underlying cause, sex and age-group, 2004: Chapter I Certain infectious and parasitic diseases. Mortality Statistics. Cause [document available on the Internet], Available from www.statistics.gov.uk\/downloads\/theme_health\/Dh2_31\/DH2No31.pdf; 2005 [accessed 15.01.09]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0285","unstructured":"Table 2.1 Deaths: underlying cause, sex and age-group, 2005: Chapter I Certain infectious and parasitic diseases. Mortality Statistics. Cause [document available on the Internet], Available from www.statistics.gov.uk\/downloads\/theme_health\/Dh2_32\/DH2_No32_2005.pdf; 2006 [accessed 15.01.09]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0290","unstructured":"Table 5.1 Deaths: underlying cause, sex and age-group, 2006: Chapter I Certain infectious and parasitic diseases. Mortality statistics. Deaths registered in 2006 [document on the Internet], Available from www.statistics.gov.uk\/downloads\/theme_health\/DR-2006\/DR_06Mort_Stats.pdf; 2008 [accessed 15.01.09]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0295","unstructured":"Table 5.1 Deaths: underlying cause, sex and age-group, 2007: Chapter I Certain infectious and parasitic diseases. Mortality statistics. Deaths registered in 2007 [document on the Internet], Available from www.statistics.gov.uk\/downloads\/theme_health\/DR2007\/DR_07_2007.pdf; 2008 [accessed 15.01.09]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0300","unstructured":"Table 5.1 Deaths: underlying cause, sex and age-group, 2008: Chapter I Certain infectious and parasitic diseases. Mortality statistics. Deaths registered in 2008 [document on the Internet], Available from http:\/\/www.statistics.gov.uk\/downloads\/theme_health\/DR2008\/DR_08.pdf; 2009 [accessed 21.07.10]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0305","unstructured":"The Information Centre for Health and Social Care. NHS Immunisation Statistics England 2008-09, Available from http:\/\/www.ic.nhs.uk\/statistics-and-data-collections\/health-and-lifestyles\/immunisation\/nhs-immunisation-statistics-england-2008-09; 2009 [accessed 20.05.11]."},{"key":"10.1016\/j.vaccine.2013.03.034_bib0310","unstructured":"Safety of meningococcal C conjugate vaccines. Current Problems in Pharmacovigilance. 2000; 26:14"},{"key":"10.1016\/j.vaccine.2013.03.034_bib0315","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4161\/hv.3.5.4458","article-title":"Post-marketing safety monitoring of a new Group B Meningococcal vaccine in New Zealand, 2004-2006","volume":"3","author":"McNicholas","year":"2007","journal-title":"Hum Vaccin"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13003691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13003691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T05:44:45Z","timestamp":1644731085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13003691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":63,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0264410X13003691"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.03.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}